Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,938.01 +935.59 (+1.40%) CMC Crypto 200
1,374.20 +43.59 (+3.28%)
Nyxoah S.A. (5YI.F)
| Previous close | 7.46 |
| Open | 7.44 |
| Bid | 7.48 x N/A |
| Ask | 8.28 x N/A |
| Day's range | 7.34 - 7.46 |
| 52-week range | 3.62 - 17.70 |
| Volume | |
| Avg. volume | 29 |
| Market cap | 270.859M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.50 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 42.13 |
GlobeNewswireNyxoah Appoints Scott Holstine as Chief Commercial Officer
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a s
- GlobeNewswire
Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (“OSA”), today announced that it has signed a €37.5 million loan facility agreement with th
- GlobeNewswire
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration (FDA). Genio
